Sponsored

GP-led deal activity is continuing apace. How should investors consider this segment in the context of their wider secondaries and PE allocations? Pantheon’s Amyn Hassanally and Kevin Dunwoodie discuss.

African dealflow has defied a global slump, but selecting investments in the right sectors and geographies remains imperative, says African Infrastructure Investment Managers’ co-managing director Olusola Lawson.

Long-term value creation will be crucial to overcoming exit challenges within the tech sector, says Vista’s founder, chairman and CEO Robert Smith.

Digital transformation is reshaping the private markets, making burdensome compliance tasks manageable and streamlining business processes, says Workiva investments industry principal Arthy Kumar.

More creative financing and deal structures will spur healthcare investment and exit activity beyond the current focus on trophy assets and add-ons, say Ropes & Gray’s Neill Jakobe and Carolyn Vardi.

The convergence of tech and biology is creating a compelling investment environment for the sector, say Brett Zbar and Mark Stevenson at General Atlantic.

Buoyed by growth trends, buyouts in the lower mid-market offer significant opportunities for value creation, says Vesey Street Capital Partners’ Adam Feinstein.

Providing inclusive and equal opportunities is closely tied to wider social and sustainability issues, all of which hinge on changing behaviours, says Ardian’s head of sustainability, Candice Brenet.

Even amid a wider dealflow drought, Germany’s mid-market is thriving. This comes as a result of relatively low PE penetration, fragmented industries and a new generation of ambitious managers.

Pharma services is creating cross-border opportunities, but GPs should be aware of regulatory and structural issues at play in different jurisdictions, say McDermott Will & Emery’s Kristian Werling and Ellie West.